V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10007561 | 10008660 | 1.83 | 76.6 | Curative (C) | 2017-02-15 | 2017-02-25 | ECX | 2 | N | 10243822 | CYCLOPHOSPHAMIDE + ETOPOSIDE |
| 10007562 | 10009200 | 1.6 | 72.6 | Palliative (P) | 2016-07-08 | 2016-07-20 | CAPECITABINE + CARBOPLATIN + Trastuzumab | 2 | N | 10244555 | FLUOROURACIL + MITOMYCIN + RT |
| 10007563 | 10005430 | 1.75 | 80.2 | Neo-adjuvant (N) | 2017-09-30 | 2017-12-07 | VEDex | null | N | 10245323 | OSIMERTINIB |
| 10007564 | 10005431 | 1.64 | 81 | Palliative (P) | 2018-07-06 | 2018-07-07 | Cisplatin + Gemcitabine (D 1 & 8) | N | N | 10245324 | IMATINIB |
| 10007565 | 10005434 | 1.59 | 116.8 | Curative (C) | 2018-05-17 | 2018-05-18 | NIVOLUMAB | N | N | 10245610 | LEAM |
| 10007566 | 10005436 | 1.69 | 78 | Palliative (P) | 2018-02-19 | 2018-02-21 | R ABVD | 02 | N | 10246569 | PILOT TRIAL |
| 10007567 | 10007698 | 1.71 | 101.9 | Disease modification (D) | 2014-06-08 | 2014-06-13 | PACLITAXEL + RAMUCIRUMAB | N | N | 10246940 | VEPEMB |
| 10007568 | 10005437 | 1.72 | 51.3 | Palliative (P) | 2017-08-31 | 2017-09-09 | VEDex | N | N | 10252742 | VEPEMB |
| 10007569 | 10005438 | 1.65 | 90.5 | Palliative (P) | 2019-06-16 | 2019-06-29 | GDP | N | N | 10252742 | THALIDOMIDE |
| 10007570 | 10005439 | 1.61 | null | Curative (C) | 2015-07-27 | 2015-07-27 | ABVD | N | N | 10258332 | FEC |
| 10007571 | 10005440 | 1.64 | 116.3 | Disease modification (D) | 2019-05-18 | 2019-05-20 | CHLORAMBUCIL + RITUXIMAB | N | N | 10264459 | LIPOSOMAL DOXORUBICIN |
| 10007572 | 10005440 | 0 | 73 | null | 2018-03-25 | 2018-03-25 | Cisplatin + Gemcitabine (D 1 & 8) | N | Y | 10264459 | CHLORAMBUCIL + OBINUTUZUMAB |
| 10007573 | 10005441 | 0 | 81.1 | Disease modification (D) | 2019-08-26 | 2019-08-26 | Panitumumab | N | N | 10266734 | MELPHALAN |
| 10007574 | 10007701 | 1.77 | 61.7 | Palliative (P) | 2017-01-15 | 2017-02-20 | QUASAR 2 TRIAL | null | N | 10268360 | HYDROXYCARBAMIDE |
| 10007575 | 10005442 | 1.84 | 52.3 | Not known (9) | 2017-11-30 | 2018-01-02 | Capecitabine (14 day) + Irinotecan | 02 | N | 10269868 | CHLVPP/PABLOE |
| 10007576 | 10005444 | 1.67 | null | Palliative (P) | 2018-04-07 | 2018-05-14 | MPV (cycle 1-4) | N | N | 10269868 | CETUXIMAB + IRINOTECAN + MDG |
| 10007577 | 10005445 | 1.82 | 92.5 | Palliative (P) | 2018-10-15 | 2019-01-04 | Hydroxycarbamide | 2 | N | 10271252 | ABVD |
| 10007578 | 10005448 | 1.69 | 62.1 | Palliative (P) | null | 2019-05-25 | BUSULFAN | 2 | N | 10272906 | ABVD R |
| 10007579 | 10005448 | 1.78 | 97.7 | Curative (C) | 2018-02-27 | 2018-02-27 | MaxiCHOP (>Cycle 2) | N | N | 10272906 | STAMPEDE TRIAL |
| 10007580 | 10005449 | 1.81 | 84 | Palliative (P) | null | 2017-02-28 | CYCLOPHOSPHAMIDE + FLUDARABINE | 02 | N | 10280634 | PAZOPANIB |
| 10007581 | 10005450 | 1.62 | 54.5 | Curative (C) | 2017-04-29 | 2017-05-18 | FEC + DOCETAXEL | N | N | 10282430 | EC |
| 10007582 | 10005452 | null | 63 | Palliative (P) | 2019-05-13 | 2019-05-20 | Panitumumab | N | Y | 10282870 | R-EPOCH |
| 10007583 | 10005454 | 1.71 | 112.8 | Disease modification (D) | 2017-09-27 | 2017-09-27 | Ipilimumab | 02 | N | 10284128 | FEC |
| 10007584 | 10005454 | 1.85 | null | Curative (C) | 2018-08-30 | 2018-09-02 | Methotrexate intrathecal | N | N | 10284128 | ENZALUTAMIDE |
| 10007585 | 10005454 | 1.79 | 83 | Palliative (P) | 2018-05-14 | 2018-05-15 | MaxiCHOP (Cycle 1) | N | N | 10284128 | ECX |
| 10007586 | 10005455 | 1.84 | 77.9 | Curative (C) | 2019-11-10 | 2019-12-23 | METHOTREXATE | 2 | N | 10286675 | CETUXIMAB + OXALIPLATIN + MDG |
| 10007587 | 10005456 | 1.72 | null | Disease modification (D) | 2016-04-01 | 2016-04-06 | CRIZOTINIB | N | N | 10304158 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 10007588 | 10005457 | 1.86 | 102 | Not known (9) | 2017-04-06 | 2017-04-27 | Cetuximab + FOLFIRI cycle 2 onwards | N | N | 10307114 | CVD |
| 10007589 | 10005457 | null | 84 | Palliative (P) | 2015-04-07 | 2015-04-17 | Hydroxycarbamide | Y | N | 10307114 | GDP |
| 10007590 | 10005457 | 1.61 | 75.8 | Palliative (P) | 2017-08-29 | 2017-09-11 | Liposomal Doxorubicin 40mg/m2 | 01 | N | 10307114 | PCV |
| 10007591 | 10005459 | 1.62 | null | Palliative (P) | 2016-01-16 | 2016-01-16 | RCEOP | 02 | N | 10320395 | EOX |
| 10007592 | 10005459 | null | 77.7 | Palliative (P) | 2019-05-21 | 2019-06-04 | Alemtuz+Fludara+Melphalan RIC MUD | 2 | N | 10320395 | MELPHALAN |
| 10007593 | 10005461 | 1.73 | 80.4 | Palliative (P) | 2016-04-04 | 2016-05-04 | Hydroxycarbamide | N | N | 10335267 | BRENTUXIMAB |
| 10007594 | 10005462 | 1.74 | null | Palliative (P) | 2014-08-24 | 2014-08-27 | Pazopanib | 01 | null | 10336154 | OXALIPLATIN + MDG + PANITUMUMAB |
| 10007595 | 10005462 | 1.7 | 91 | Curative (C) | 2019-04-05 | 2019-04-06 | ATG + Busulfan + Fludarabine | 2 | N | 10336154 | BEVACIZUMAB + CARBO + PACLITAXEL |
| 10007596 | 10005464 | 1.77 | 55.7 | Palliative (P) | 2018-04-27 | 2018-05-26 | Vinorelbine IV | 02 | N | 10336923 | BORTEZOMIB |
| 10007597 | 10005465 | 1.79 | 105.7 | Palliative (P) | 2018-12-19 | 2019-04-22 | RUXOLITINIB | N | Y | 10337522 | CHLORAMBUCIL + RITUXIMAB |
| 10007598 | 10005465 | 1.7 | 51 | Curative (C) | 2014-08-26 | 2014-10-10 | IMATINIB | 02 | N | 10337522 | FCR |
| 10007599 | 10005466 | 1.67 | 77.8 | Palliative (P) | 2018-03-01 | 2018-03-04 | LANREOTIDE | 02 | N | 10338618 | BORTEZOMIB + THALIDOMIDE |
| 10007600 | 10005467 | 1.77 | 76.3 | Palliative (P) | 2017-07-25 | 2017-07-26 | CARBOPLATIN + RT | N | N | 10339492 | CISPLATIN |
| 10007601 | 10005468 | 1.72 | 94.15 | Not known (9) | 2017-02-08 | 2017-02-13 | Bortezomib + CYCLOPHOSPHAMIDE | 2 | N | 10339585 | BUSULPHAN |
| 10007602 | 10005468 | 1.86 | 126.8 | Curative (C) | 2018-12-21 | 2019-01-15 | Cladribine (subcut) 5 days | 02 | N | 10339585 | AFATINIB |
| 10007603 | 10005469 | null | 69.5 | null | 2016-11-21 | 2016-12-12 | VEDex | N | N | 10344577 | THALIDOMIDE |
| 10007604 | 10005470 | 1.59 | 57.38 | null | 2018-01-04 | 2018-02-06 | PERTUZUMAB + TRASTUZUMAB | N | N | 10349347 | CYCLOPHOSPHAMIDE + DOCETAXEL + TRASTUZUMAB |
| 10007605 | 10005470 | 1.75 | 69.55 | Not known (9) | 2018-05-25 | 2018-06-15 | Gemcitabine + Capecitabine | 2 | N | 10349347 | CAPECITABINE + CARBOPLATIN |
| 10007606 | 10005470 | 1.75 | null | Neo-adjuvant (N) | 2018-09-11 | 2018-09-14 | Temozolomide + RT | null | N | 10349347 | DOCETAXEL + NINTEDANIB |
| 10007607 | 10005471 | 1.72 | 86 | Adjuvant (A) | 2017-08-23 | 2017-09-14 | BOSUTINIB | 01 | N | 10361215 | QUASAR 2 TRIAL |
| 10007608 | 10005472 | 0 | 73.6 | Adjuvant (A) | 2019-02-02 | 2019-02-09 | Erlotinib | N | N | 10363220 | ERLOTINIB |
| 10007609 | 10005472 | 1.74 | 93.7 | Not known (9) | 2015-06-13 | 2016-02-02 | ECX | null | N | 10363220 | CYTARABINE + RITUXIMAB |
| 10007610 | 10005472 | 1.79 | 94 | Palliative (P) | 2017-07-04 | 2017-07-05 | Erlotinib | N | N | 10363220 | CETUXIMAB + RT |